# Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years.

- **DOI:** [10.1159/000546987](https://doi.org/10.1159/000546987)
- **Rating:** Limited (2.5 out of 5)
- **Verdict:** Long-term lanadelumab observations document improvement among persistent users, but the uncontrolled retrospective design cannot establish treatment effects.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-02
- **Evaluation page:** https://www.nabu.science/paper/10.1159%2F000546987

## Key claims

1. In conclusion, treatment with lanadelumab LTP for at least 3 years reduced the severity and frequency of attacks and improved QoL in patients with HAE.
   - Support: Tentative
   - Type: Primary finding
   - Basis: uncontrolled retrospective observations among persistent users cannot identify a causal treatment effect
   - Location: Discussion, final paragraph (conclusion)
2. The proportion of patients experiencing at least 1 attack per month on average decreased from 54.0% (27 of 50) prior to lanadelumab initiation to 9.8% (5 of 51) at the time of the survey.
   - Support: Supported
   - Type: Secondary
   - Basis: reported counts support the descriptive decrease among selected long-term users, despite retrospective reporting and no comparator
   - Location: Results, Attack Frequency
3. The proportion of patients with good or excellent QoL increased from 68.6% before lanadelumab initiation to 88.2% at the time of the survey.
   - Support: Tentative
   - Type: Secondary
   - Basis: retrospective, unvalidated physician-rated QoL limits certainty about patients' experienced improvement
   - Location: Abstract Results; Results, Health-related QoL

## Strengths

- **Longer observation extends rare disease evidence** The analysis reports outcomes before treatment and at 12, 24, and 36 months among 51 patients receiving lanadelumab for at least three years. This adds longer-term descriptive observations to the earlier 12-month analysis.
  - Dimension: contribution
  - Location: Methods, Assessments; Introduction, final paragraph; Results
- **Explicit denominators make descriptive findings traceable** Outcome proportions generally include their numerators and denominators, and the analysis states that varying sample sizes reflect missing or incomplete reporting. The printed counts support the reported attack-frequency and QoL percentages.
  - Dimension: reporting
  - Location: Methods, Statistical Analysis; Results, Attack Frequency and Health-related QoL
- **Findings connected to established clinical evidence** The Discussion compares the observations with HELP, EMPOWER, earlier Adelphi outcomes, and other real-world studies. It also identifies recall, selection, missingness, and subjective assessment as limitations.
  - Dimension: positioning
  - Location: Discussion, literature-comparison and limitations paragraphs

## Limitations

- **Causal conclusion exceeds the uncontrolled design** The final conclusion attributes improvements to lanadelumab, but the single-arm retrospective survey cannot separate treatment effects from regression to the mean, natural history, or other changes.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Statistical Analysis; Discussion, final paragraph
- **Persistent user selection limits broader applicability** Eligibility requires at least three years of continuous lanadelumab-only prophylaxis. Patients who discontinued, switched, or added another prophylactic treatment are excluded, so the findings describe continuers rather than everyone starting treatment.
  - Dimension: methodological rigour
  - Location: Methods, Study Design
- **Retrospective physician ratings constrain outcome certainty** Severity and QoL were reconstructed from medical records and physician judgment, without validated patient-reported QoL measures. Missing reporting and uncharacterized measurement error further limit confidence in the trajectories.
  - Dimension: methodological rigour
  - Location: Methods, Assessments and Statistical Analysis; Discussion, limitations paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. The attack-frequency categories defined in Methods differ from those reported in Results. Ethics review, sponsorship, conflicts of interest, and a named data-access route are disclosed.
  - Conflict of interest: declared · Ethics approval: declared · Data availability: declared
- **Reference integrity:** Clean
  - 24 references in manuscript
  - 22 of 22 checkable references found in an index
  - 2 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-02
